Anti-p200 pemphigoid has been characterized by autoantibodies to an unidentified 200-kDa protein (p200) of the dermal؊epidermal junction. The objective of this study was to identify p200. We performed 2D gel electrophoresis of dermal extracts and immunoblotting with patients' sera, followed by MS analysis of a unique protein band. The protein band corresponded to laminin ␥1. Anti-laminin ␥1 mAb reacted with the anti-p200 immunoprecipitates by immunoblotting. Sera from 32 patients with anti-p200 pemphigoid showed 90% reactivity to the recombinant products of laminin ␥1. None of the healthy control sera reacted with laminin ␥1. By immunoblotting, reactivity of a patient's serum with p200 was competitively inhibited by adding anti-laminin ␥1 C-terminus mAb. Purified anti-p200 IgG also inhibited the reactivity of this mAb to dermal laminin ␥1. Most laminin ␥1-positive sera showed reactivity with recombinant laminin ␥1 C-terminal E8 fragment. Reactivity of patients' sera and purified IgG to dermal laminin ␥1 was higher than reactivity to blood vessel laminin ␥1 under reducing conditions. These results suggest that laminin ␥1 is the autoantigen for patients with anti-p200 pemphigoid. The autoantibodies may specifically recognize dermal laminin ␥1 with unique posttranslational modifications. The epitope is localized to the 246 C-terminal amino acids within the coiled-coil domain. The 9 C-terminal residues are known to be critically involved in laminin recognition by integrins.
A nti-p200 pemphigoid is a novel autoimmune subepidermal blistering diseases (1, 2) . It is characterized by autoantibodies against a 200-kDa protein (p200) of the dermal-epidermal junction. This protein has been shown to be distinct from all other known autoantigens within the dermal-epidermal anchoring complex (3, 4) , including type XVII collagen (BP180) (5), bullous pemphigoid antigen 1 (BP230) (6) , ␣6␤4 integrin (7), laminins 332 and 311 (8, 9) , and type VII collagen (10) .
Clinically, most reported cases present with tense blisters and urticarial eruptions, symptoms that are different from those of any established bullous disease but closely resemble bullous pemphigoid (11) . Following our first cases described in 1996 (1, 2), more than 50 cases have been published (12) . So far, the identity of the protein has remained an enigma.
Previous attempts to characterize p200 localized this autoantigen to the lower lamina lucida by indirect immunogold electron microscopy (1) . A polyclonal anti-laminin 1 antibody stained the similar 200-kDa band by immunoblotting with extracts of cultured human fibroblasts and dermal extracts (1, 11) . However, serum from an anti-p200 pemphigoid patient could not react detectably with purified laminin 111 by immunoblot study under reducing conditions (1) . Further, by indirect immunofluorescence, the antilaminin 111 antibody reacted with both the dermal basement membrane zone and vessels, whereas patients' sera reacted only with the dermal basement membrane zone (1, 11) . Indirect immunofluorescence with skin lacking laminin 332 and type VII collagen showed that p200 does not correspond to these proteins (3, 4) . Biochemically, p200 is a noncollagenous N-glycosylated acidic protein (13) that is distinct from subunits of type VI collagen (13) and nidogen 2 (14) .
Here, we report that laminin ␥1 is the autoantigen in patients with anti-p200 pemphigoid.
Results

Characterization of a Unique Immunoreactive Protein Band from
2D-Separated Dermal Extracts. Dermal extracts were separated by 2D electrophoresis with an isoelectric focusing between isoelectric point (pI) 4 and 7, followed by 7.5% SDS gel electrophoresis. Each extract was run on 2 gels; 1 gel was stained with Coomassie brilliant blue (Fig. 1A) , and the other was transferred onto a nitrocellulose membrane, followed by immunoblotting with serum from a patient with anti-p200 pemphigoid (Fig. 1B) . The serum detected multiple bands migrating around pI 5.0 and in the 120-250-kDa region, the most reactive band of which was located at 250 kDa. The identical band on the Coomassie-stained gel was analyzed by MS (Fig. 1D) . A database search characterized the protein band as laminin ␥1, nominal mass 184,596, calculated pI value 5.01, with 28% of sequence coverage (Fig. 1E) . To confirm the identity of the particular band, immunoblotting using anti-laminin ␥1 mAb was performed on the membrane to which 2D-separated dermal extracts were transferred. The patient's serum and the mAb reacted with the same bands (Fig. 1C ). Sera from 3 additional patients also labeled the same bands (not shown).
Anti-laminin ␥1 mAb reacted with an immunoprecipitate formed of anti-p200 pemphigoid serum and dermal extract, but the antibody did not react with an immunoprecipitate of healthy control serum ( Fig. 2A) . The supernatant of immunoprecipitation of a dermal extract with patient serum was tested for immunoblotting with anti-laminin ␥1 mAb: no band was detected, suggesting that all laminin ␥1 was completely adsorbed by the patient serum. Inversely, on immunoblotting, immunoprecipitates with anti-laminin ␥1 mAb reacted with patients' sera in a dose-dependent manner (Fig. 2B) . The supernatant of anti-laminin ␥1 immunoprecipitation showed reactivity to anti-p200 pemphigoid serum in inverse proportion to the amount of anti-laminin ␥1 antibody used. The results of immunoblotting with anti-p200 pemphigoid sera suggest that the ␥1 chain of laminins is the dermal component of the p200 band.
Reactivity of Patients' Sera with Laminin ␥1. To investigate whether the reactivity of the patient serum with laminin ␥1 is shared among patients with anti-p200 pemphigoid, the sera from 20 representative patients were examined for their reactivity toward purified laminin 111 and laminin 211/221, both of which contain the laminin ␥1 chain. All 20 sera reacted with the 200-kDa protein on immunoblotting using dermal extract, and the position of the band coincided with that of the band detected with anti-laminin-␥1 mAb (Fig. 3A) , thus supporting the possibility that the autoantigen in anti-p200 pemphigoid is laminin ␥1. Consistent with this possibility, 80% and 85% of the patients' sera reacted positively with the ␥1 chains of purified laminin 111 and laminin 211/221, respectively (Fig. 3, B and C, and Table 1 ). Sera from a total of 32 patients showed comparable reactivity (not shown). These results were confirmed further by immunoblot analysis using recombinant products of laminin 111, in which 90% of the patients' sera showed evident reactivity to the recombinant laminin ␥1 (Fig. 3D and Table 1 ). Importantly, no sera from the 9 healthy controls reacted with purified or recombinant laminin ␥1. Sera from patients with other bullous diseases, such as bullous pemphigoid, anti-laminin 332 mucous membrane pemphigoid, and epidermolysis bullosa acquisita, showed no reactivity to laminin ␥1 (not shown). These results suggest that laminin ␥1 is the exclusive autoantigen in anti-p200 pemphigoid, although there were a few negative cases.
Responsible Epitope on Laminin ␥1. By immunoblotting, reactivity of a patient's serum to the p200 from dermal extract was competitively inhibited by adding anti-laminin ␥1 C-terminus mAb (lanes B-4), but not by adding anti-laminin ␥1 N terminus mAb (lanes C-13S) or anti-collagen VI mAb (lanes 3C4) (Fig. 4A ). Serum and purified IgG from an anti-p200 pemphigoid patient inhibited the reactivity of the mAb B-4 to dermal laminin ␥1 in a dose-dependent manner, but healthy control serum or IgG did not (Fig. 4B) . These results indirectly showed that the reactive site on the dermal p200 protein for the patient's serum was located at the laminin ␥1 C-terminus.
To narrow down further the responsible epitope within the laminin ␥1 chain, we produced a recombinant ''E8 fragment'' of human laminin 111, a truncated version of laminin 111 comprising the C-terminal 25% of the coiled coil domain and 3 laminin G-like modules (i.e., LG1-3) of laminin 111 (Fig. 5A ). Immunoblot analyses using this recombinant protein showed that most laminin ␥1-positive sera showed reactivity with the laminin ␥1 E8 fragment under both reduced and nonreduced conditions (Fig. 5B) . The results of immunoblot analyses obtained with sera from 20 different patients are summarized in Table 1 . These results suggest that the putative epitope targeted by patients' autoantibodies is located within the C-terminal 246-amino acid residues of the laminin ␥1 chain.
Organ Specificity of the Autoantibodies. Indirect immunofluorescence microscopy on 1 M NaCl-split human skin sections showed that purified IgG from anti-p200 pemphigoid patients reacted with the dermal side of the split (Fig. 6A and B) . IgG from a particular case also reacted with vessel walls of the capillaries in the papillary dermis (Fig. 6B) . However, other patients' IgG showed no visible reactivity with blood vessels (Fig. 6A) , a finding that is consistent with previously reported results (1, 11) . In contrast, anti-laminin ␥1 mAb C13S reacted with both the dermal side of the split skin and vessel walls (Fig. 6C) .
In immunoblot studies under reducing conditions, the loaded amounts of extracts of dermis and the vessels were adjusted by the reactivity of anti-laminin ␥1 mAb B-4 (Fig. 6D, Lower) . In the same immunoblotting, reactivity of purified IgG from patient #20 to the dermal laminin ␥1 was much higher than reactivity to blood vessel laminin ␥1 (Fig. 6D, Upper) . This observation was reproducible using sera from several other patients (not shown). However, purified IgG from patient #12, which reacted with the basement membrane zones of both dermis and vessel by indirect immunofluorescence microscopy, showed comparable immunoblot reactivity with laminin ␥1 extracted from dermis and blood vessels (Fig.  6D, Middle) . Except for this case, these results suggest that circulating IgG antibodies in patients with anti-p200 pemphigoid react with laminin ␥1 within the dermal basement membrane zone but have much less reactivity with laminins in blood vessel walls.
Discussion
In this study, we identified laminin ␥1 as the autoantigen in anti-p200 pemphigoid by MS analysis. We confirmed this result by several immunoblot approaches using anti-laminin ␥1 mAb. Both anti-laminin ␥1 mAb and anti-p200 pemphigoid serum reacted with an identical band in 2D-separated dermal extracts. Moreover, immunoprecipitates of anti-p200 pemphigoid serum reacted positively with anti-laminin ␥1 mAb. Also, reactivity of anti-200 pemphigoid serum with dermal extracts was competitively inhibited by anti-laminin ␥1 mAb, and vice versa.
Laminin ␥1 is a 200-kDa N-linked glycoprotein (15) that is present in the cutaneous basement membrane zone. These molecular characteristics are the same as those of p200 defined previously (13, 14) , so it is quite reasonable to conclude that it is the autoantigen of this autoimmune subepidermal blistering disease. Laminin ␥1 is a component of different forms of laminin heterotrimers, such as laminin 311/321 and 511 (16) . It contributes to dermal-epidermal adhesion outside hemidesmosomes (16) . A laminin ␥1 gene knockout results in embryonic lethality at day 5 because of the failure to form basement membranes, which are prerequisites for embryonic ectoderm differentiation (17) . Functional inhibition of laminin ␥1 by a nidogen-binding laminin ␥1-chain fragment resulted in complete suppression of basement membrane formation in a 3D coculture of human skin keratinocytes and fibroblasts (18) .
Our immunoblot analyses demonstrated that most patients' sera reacted with recombinant forms of laminin ␥1. This result negates the possibility that patients' sera actually reacted with contaminating proteins of 200-kDa molecular weight that are associated with laminins, such as nidogens and collagen fragments. A few laminin ␥1-negative sera were present, but all patients' sera reacted with p200 from dermal extracts by immunoblotting. This discrepancy could be explained by differences in sensitivity of the different assays. The laminin ␥1-negative sera showed weak reactivity with p200 from dermal extracts but did not show visible reactivity to purified or recombinant laminins, perhaps because of distinct posttranslational modifications that are different from those of dermal laminins. Another, less likely but possible, explanation for the discrepancy between immunoblot results obtained using dermal extracts and different laminin preparations is that p200 may be a heterogeneous protein, although laminin ␥1 certainly is a major component.
A previous study to identify p200 using the same technique showed that p200 is a non-collagenous N-linked glycoprotein with a pI of 5.4-5.6 (13) . In that study the ␣3 chain of type VI collagen was a candidate for p200, but patients' sera did not react with the purified ␣3 chain of type VI collagen by immunoblotting (13) . We reproduced these results in some patients' sera and confirmed that the ␣3 chain of type VI collagen with a pI of 5.4-5.6 is not p200 (not shown). Although in previous studies we had suggested the possibility that p200 is laminin ␥1 (1, 11) , we could not detect any reactivity of sera from some previous cases of anti-p200 pemphigoid to placental laminin (11), purified laminin 111 (1, 11), or laminin 311 (11) by immunoblotting under reducing conditions. Nevertheless, by using multiple approaches with improved sensitivity and specificity, the present study strongly suggests that p200 is laminin ␥1.
A few healthy control sera showed a weak reactivity with the laminin 111-E8 fragment under nonreducing conditions (Fig. 5B , Lower Column, and Table 1 ), but the reactivity of patients' sera was much stronger. These results may be caused by an unspecific reactivity, as has been described for other autoantigens of autoimmune bullous diseases, or by nonspecific bands derived from cell lines used for expression of the recombinant protein mimicking the molecular weight of the recombinant products (19) .
In our study, most laminin ␥1-positive sera showed reactivity with the recombinant C-terminal fragment of laminin ␥1. Among laminin heterotrimers, the laminin ␥1 C-terminus interacts with different integrins such as ␣3␤1 and ␣6␤4 integrins in the cutaneous basement membrane zone (20, 21) . We reported previously that the glutamic acid residue at the third position from the C-terminus of laminin ␥1 is required for integrin binding by laminin trimers (21) . One therefore may speculate that anti-laminin ␥1 autoantibodies modify the laminin-integrin interaction by interfering with the intrinsic binding site used for connecting these molecules in patients' skin in a direct or indirect manner. Interaction of laminin ␥1 with the nidogen anchors laminin ␥1 to the type IV collagen in the basement membrane zone (22, 23) . Whether patients' sera react with nidogen-binding sites on the laminin ␥1 molecule needs further clarification.
Anti-laminin ␥1 autoantibodies from patients with anti-p200 pemphigoid are associated with skin blisters but show no pathology in other organs, although laminin ␥1 is widely expressed in different basement membrane zones. The results of immunoblot studies suggest that laminin ␥1 in the epidermal basement membrane zone may have different posttranslational modifications, such as glycosylation, compared with laminin ␥1 expressed in blood vessels (Fig.  6D) . Differences in posttranslational modification may allow further possible explanations for the organ specificity of the disease. Specifically, differences in posttranslational modification could result in (i) different 3D structures of laminin trimers within each organ, (ii) differences among associating molecules, such as integrin dimers, or (iii) organ-specific function by intermolecular associations, which can be specifically targeted by autoantibodies. Circulating anti-laminin ␥1 autoantibodies in the patients may inhibit specific laminin-integrin interactions in the skin, which have an intrinsic role within the dermal-epidermal junction but are dispensable in other organs. Fig. 4 . Reactivity of anti-p200 pemphigoid sera to the laminin ␥1 C-terminal portion. (A) In immunoblotting with dermal extracts (7.5% SDS), reactivity of a patient's serum to p200 (closed arrow) was reduced by adding anti-laminin ␥1 mAb B-4 (B-4, 2 and 10 g/ml), recognizing the C-terminus of this protein in a dose-dependent manner. Normal human IgG (Normal IgG), anti-laminin ␥1 N-terminal mAb (C13S), or anti-collagen VI mAb (3C4, in ascites) did not inhibit binding of patient's serum to p200 from dermal extracts. The indicated doses of IgG (g/ml), ascites, or sera (l) were added or not (Ϫ) to each cellulose membrane during the reaction. (B) Serum and purified IgG from a patient with anti-p200 pemphigoid reduced binding of mAb B-4 to laminin ␥1 extracted from dermis (open arrow), but serum or IgG from a healthy control did not. Summary of the reactivity of sera from 20 patients with anti-p200 pemphigoid and healthy controls to laminin ␥1 by  immunoblot analyses in Figs. 3 In conclusion, we have demonstrated that autoantibodies from patients with anti-p200 pemphigoid react with laminin ␥1. Therefore, we propose a new name, anti-laminin ␥1 pemphigoid, for this autoimmune bullous disease. Future studies will aim at providing direct evidence of the pathogenic role of anti-laminin ␥1 autoantibodies. In addition, it will be of interest to investigate whether anti-laminin ␥1 autoantibodies affect a specific interaction between laminin ␥1 and its ligands within the cutaneous basement membrane zone.
Materials and Methods
Patients. All described studies were performed following the guidelines of the medical ethics committee of Kurume University School of Medicine. All participants in this study provided informed consent, and these studies were conducted according to the Declaration of Helsinki Principles. Thirty-two patients (10 males, 6 females, and 16 of unreported sex, 17-87 years old) were diagnosed as having anti-p200 pemphigoid by their clinical course and manifestation of blister formation, indirect immunofluorescence with 1 M NaCl-split skin demonstrating IgG reactivity with the dermal side of the basement membrane zone, and Western blotting with dermal extracts showing a 200-kDa band. Sera from 9 healthy volunteers and from patients with bullous pemphigoid, anti-laminin 332 mucous membrane pemphigoid, and epidermolysis bullosa acquisita were used as controls.
Antibodies. Mouse anti-laminin ␥1 mAb B-4 was purchased from Santa Cruz Biotechnology. Mouse anti-laminin ␥1 mAb C13S was produced in our laboratory (20, 24). Mouse anti-collagen VI mAb, 3C4, and mouse control IgG were purchased fromChemicon, Millipore, and Santa Cruz Biotechnology, respectively. The second antibodies, rabbit anti-human IgG or mouse Ig antisera conjugated with horseradish peroxidase and rabbit anti-human IgG or mouse Ig antisera conjugated with fluorescein isothiocyanate, were purchased from (Dako Corporation). IgG from patients' sera and healthy controls were purified on a HiTrap Protein G HP column (Amersham Biosciences).
Preparation of Dermal and Blood Vessel Extracts.
Dermal extract for immunoblot analysis was prepared according to the method reported previously (11) . The extract of blood vessels was prepared by a similar method with several modifications. Mesenteric arteries from which adventitia had been removed were incubated in PBS containing 2 mM EDTA and 2 mM PMSF for 2 d at 4°C. Blood vessel proteins were extracted with 8 M urea, 0.3 M ␤-mercaptoethanol, and 1 mM PMSF in 25 mM Tris (pH 6.8) for 2 h at room temperature. The vessel extract was dialyzed for 2 d at 4°C against H2O and was precipitated by adding an equal volume of acetone.
Preparation of Laminins.
Human laminin 111 was purified from the JAR human choriocarcinoma cell line, and laminin 211/221 was purified from human placenta (20) . Recombinant laminin 111 was produced by transfecting human 293-F cells (Invitrogen) with expression vectors encoding human ␣1/␤1/␥1 chains (21) .
A recombinant E8 fragment of laminin 111, a heterotrimer of the truncated C-terminal portions of ␣1, ␤1, and ␥1 chains, was prepared as follows. Expression vectors for the recombinant E8 fragment of human laminin ␤1 and ␥1 (coding Leu 1561 -Leu 1786 and Asn 1364 -Pro 1609 , respectively) were prepared as described previously (21) . cDNA encoding the truncated C-terminal portions (Phe 1878 -Gln 2700 ) of the laminin ␣1 chain was amplified by PCR using full-length human laminin ␣1 expression vector as a template (25) and was inserted into the expression vector pSecTag2A (Invitrogen). A recombinant E8 fragment of laminin 111 was produced using the Free-Style TM 293 Expression system (Invitrogen) and was purified from conditioned medium as described previously (21) . Briefly, the conditioned media were applied to nickel nitrilotriacetic acid affinity columns (Qiagen), and bound proteins were eluted with 200 mM imidazole. The eluted proteins were purified further on anti-FLAG columns (Sigma-Aldrich Inc.). The purified protein was dialyzed against TBS. Protein concentration was determined by the BCA TM Protein Assay Kit (Pierce Biotechnology).
Immunoblot Analyses. SDS/PAGE was performed as described previously (26) . Extracts of dermis and blood vessels, human laminins, and human laminin-E8 fragment were boiled in Laemmli's sample buffer with or without 5% ␤-mercaptoethanol and were fractionated on 6%, 7.5%, or 12% SDS gels. Subsequently, IgG from case #20 did not react with blood vessels in the upper dermis (A), whereas IgG from case #12 did (B). (C) Anti-laminin ␥1 mAb C13S showed reactivity with both the dermal side of the basement membrane zone and blood vessel walls in the dermis. (D) Immunoblotting with extracts of dermis and blood vessels. The amount of extract loaded was adjusted by the reactivity of antilaminin ␥1 mAb B-4 (Bottom). Under reducing conditions, reactivity of the patient's purified IgG from case #20 (also used in Fig. 6A ) to the dermal laminin ␥1 was much higher than reactivity with blood vessel laminin ␥1 (Top). Purified IgG from case #12 (also used in Fig. 6B ) showed similar reactivity with laminin ␥1 from dermal extract and blood vessel extract (Middle). Lane 1, purified laminin 111 from the JAR cell line; lane 2, dermal extract; lane 3, extract of vessels (7.5% SDS, under reducing conditions).
